Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings is an early-stage biopharmaceutical company focused on developing sublingual drug delivery technologies. The company's lead product, Instaprin, is a soluble, pH-neutral aspirin formulation designed for rapid absorption under the tongue, targeting acute cardiology emergencies and pain management applications.

Beyond Instaprin, the company is developing a pipeline of sublingual formulations across multiple therapeutic categories. Current development candidates include melatonin for sleep, vitamins D, E, and K, testosterone replacement therapy, and semaglutide for weight management. The company is also pursuing sublingual versions of anti-nausea medications, antipsychotics, erectile dysfunction drugs, and seizure medications, alongside caffeine-based products marketed as pre-workout supplements.

Founded in 2021 and based in Estero, Florida, the company operates at an early development stage with limited public financial disclosures regarding employee count or revenue generation. Aspire Biopharma is traded on the Nasdaq and incorporated in the Cayman Islands.